Abstract
Survival of patients with pancreatic neuroendocrine tumor is determined by many factors. An important role is played by accurate selection of patients for different treatment modalities, that is clearly determined by adequate cancer staging. To date there are two TNM-classifications of pancreatic neuroendocrine tumors which are differ greatly among themselves - European Neuroendocrine Tumor Society TNM-staging system (2006) and American Joint Cancer Committee TNM staging system (2010). We have reviewed the most significant publications related to the analysis of TNM systems accuracy for these tumors. These data suggest that European Neuroendocrine Tumor Society TNM-staging system is superior to the American Joint Cancer Committee TNM-staging system. Considering the low incidence of pancreatic neuroendocrine tumors only further large multi-center studies will improve the staging of these tumors.
Highlights
Survival of patients with pancreatic neuroendocrine tumor is determined by many factors
An important role is played by accurate selection of patients for different treatment modalities, that is clearly determined by adequate cancer staging
We have reviewed the most significant publications related to the analysis of TNM systems accuracy for these tumors. These data suggest that European Neuroendocrine Tumor Society TNM-staging system is superior to the American Joint Cancer Committee TNM-staging system
Summary
Глотов А.В.*, Калинин Д.В., Смирнов А.В., Кригер А.Г. ФГБУ “Институт хирургии им. Выживаемость пациентов с нейроэндокринной опухолью поджелудочной железы определяется множеством факторов. На сегодняшний день существуют две TNMклассификации нейроэндокринной опухоли поджелудочной железы, которые существенно различаются между собой, – классификация Европейского общества нейроэндокринных опухолей (2006) и классификация Американского объединенного онкологического комитета (2010). We have reviewed the most significant publications related to the analysis of TNM systems accuracy for these tumors These data suggest that European Neuroendocrine Tumor Society TNM-staging system is superior to the American Joint Cancer Committee TNM-staging system. Нейроэндокринная опухоль (НЭО) поджелудочной железы, согласно определению Всемирной организации здравоохранения (ВОЗ), является злокачественной эпителиальной опухолью с преимущественно нейроэндокринной дифференцировкой [1]. ВОЗ рассматривала НЭО поджелудочной железы в контексте опухолей органов эндокринной системы (классификация 2004 г.), тогда как НЭО желудка и тонкой кишки относились к опухолям органов пищеварительной системы и были включены в состав классификации наряду с другими эпителиальными и неэпителиальными опухолями этих органов (классификация 2000 г.) [3, 4]. До 2006 г. отсутствовала TNM-классификация НЭО поджелудочной железы
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
